Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges
Company Announcements

Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges

The latest announcement is out from Virpax Pharmaceuticals (VRPX).

Virpax Pharmaceuticals, Inc. has been given until September 30, 2024, to meet Nasdaq’s minimum stockholders’ equity requirement after falling short earlier in the year. At the company’s Annual Meeting, shareholders approved amendments to increase the number of shares available under the 2022 Equity Incentive Plan and the percentage of reserved shares for annual issuance. Additionally, Eric Floyd and Gary Herman were elected as directors, and EisnerAmper LLP was ratified as the independent accounting firm for the upcoming year.

See more insights into VRPX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAdial Pharmaceuticals appoints Shah as Chief Financial Officer
TheFlyVirpax Pharmaceuticals downgraded to Hold from Buy at Maxim
TipRanks Auto-Generated NewsdeskVirpax Pharmaceuticals Faces Nasdaq Delisting Risk
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App